
==== Front
BiologicsBiologicsBiologics: Targets & TherapyBiologics : Targets & Therapy1177-54751177-5491Dove Medical Press 10.2147/BTT.S87768btt-9-045CorrigendumNew product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis [Corrigendum] 2015 29 6 2015 9 45 45 © 2015 Frati et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License2015The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
==== Body
Frati F, Cecchi L, Scala E, Ridolo E, Dell’Albani I, Makrì E, Pajno GB, Incorvaia C. Biologics: Targets and Therapy. 2014;8:221–226.

On page 223, Figure 1 should be replaced with the revised version as shown below:

On page 224, line 4 in the left column, “many” should be replaced with “all”.

On page 224, line 7 in the left column, “but only the major allergen Phl p 5 is measured in μg” should be replaced with “such as group 1 and group 5 allergens (Figure 1, Table 2)”.

On page 224, line 9 in the left column, the reference to “(Figure 1)” should be removed.

Figure 1 The molecular profile of Staloral biomolecular grasses.
